GlassScriptPhysician profile
Thuhanh Johnson
NPI 1982329462
$2,236.27
in general payments reported to CMS, 2019-2025
21 companies · $46.71 in 2025
The $46.71 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.98 · 2023: $742 · 2024: $1,425 · 2025: $46.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.34 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.76 | 2023-2025 | |
| Novo Nordisk INC | $327.03 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $206.05 | 2024 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $190.41 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $150.37 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.48 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $133.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $112.90 | 2023 | Uptravi, Opsumit |
| Pfizer INC. | $81.43 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.10 | 2023 | Gattex |
| Sumitomo Pharma America, INC. | $71.11 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $64.65 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $54.30 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $44.28 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $39.33 | 2023-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.52 | 2024 | Veozah |
| Amgen INC. | $32.47 | 2023 | Evenity, Prolia |
| Sunovion Pharmaceuticals INC. | $21.98 | 2022 | |
| Radius Health, INC. | $19.66 | 2024 | Tymlos |
| Lundbeck LLC | $19.09 | 2024 | Rexulti |
| Corcept Therapeutics | $18.29 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuhanh Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.